AbelaDrug200

Developed for: brain injury
Investigated by: Abela Pharmaceuticals, Inc. · Dr. Mahajan's Hospital & Industrial Trauma Centre · Ohio State University · University of California, Irvine

today NCT00810940 · Ph 1/2

20112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT00810940	Oct 2010 → Dec 2011	brain injury	Abela Pharmaceuticals, Inc.	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	AbelaDrug200	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00810940 ↗
Route	Intravenous	“then IV 100 ml same schedule for 24 hours” NCT00810940 ↗